In recent years, the application of ADC drugs in breast cancer therapy has become increasingly widespread, especially HER2 ADC drugs have displayed significant efficacy in the second-line and late-line treatments of advanced breast cancer, becoming a research hotspot in this field. This evidence concerns the gene ERBB2 and breast carcinoma.